Related Experiment Video
Updated: Jul 24, 2026
19:15
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
85.8K
Practical Application of Nirsevimab Recommendations for Infants and Toddlers
Summary
Nirsevimab offers 90% protection against severe respiratory syncytial virus (RSV) hospitalization in infants. This long-acting antibody provides crucial prevention for vulnerable populations, addressing caregiver hesitancy and health equity concerns.
Area of Science:
- Pediatrics
- Infectious Diseases
- Immunology
Background:
- Respiratory syncytial virus (RSV) is a primary cause of infant hospitalization due to bronchiolitis and pneumonia.
- Severe RSV disease disproportionately affects infants and young children.
- Nirsevimab is a novel long-acting monoclonal antibody for RSV prevention.
Purpose of the Study:
- To review the mechanism of action, safety, and efficacy of nirsevimab.
- To outline prescribing recommendations for nirsevimab in infants and high-risk toddlers.
- To address challenges in nirsevimab implementation, including caregiver hesitancy and health equity.
Main Methods:
- Review of recent clinical trial data on nirsevimab efficacy.
- Analysis of nirsevimab's pharmacokinetic and pharmacodynamic properties.
- Consideration of public health guidelines and special prescribing circumstances.
Main Results:
- Nirsevimab demonstrated 90% protection against severe RSV disease hospitalization in infants during their first RSV season.
- The monoclonal antibody is recommended for all infants under 8 months and certain high-risk toddlers.
- Implementation requires addressing caregiver concerns and ensuring equitable access.
Conclusions:
- Nirsevimab is a highly effective tool for preventing severe RSV disease in infants.
- Understanding nirsevimab's profile is crucial for healthcare providers to optimize its use.
- Special populations and potential drug shortages necessitate careful, equitable prescribing strategies.
Related Concept Videos
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...